Ï Ó. åîïìïëïãåßôáé...

Boy Äéáãíþóèçêá ïñïèåôéêüò ôïí ðåñáóìÝíï ÖåâñïõÜñéï.

Áðü ôçí ðñþôç óôéãìÞ, åßðá óôïí åáõôü ìïõ üôé èá áíôéìåôùðßóù áõôÞ ôçí êáôÜóôáóç ìå äýíáìç, ãéáôß åßíáé ï ìüíïò ôñüðïò.

Ôï åßðá óå 2 ößëïõò ìïõ. Ôïõò âïÞèçóá íá ìçí ôï ðÜñïõí êáôÜêáñäá, íá ìçí äåßîïõí üôé ìå ëõðïýíôáé êáé íá ìçí áëëÜîïõí óõìðåñéöïñÜ áðÝíáíôé ìïõ, ìå ôï íá ôïõò äåßîù üôé êáé åãþ ï ßäéïò äåí ëõðÜìáé ôïí åáõôü ìïõ, êáé åãþ ï ßäéïò äåí Üëëáîá. Ìïõ ëÝíå üôé äåí ðåñßìåíáí ðïôÝ íá åßìáé ôüóï äõíáôüò.

Ç ïéêïãÝíåéá ìïõ, óå ðëÞñç Üãíïéá... Êáé Ýôóé ðñÝðåé. Åßíáé üìùò óôéãìÝò ðïõ èÝëù íá îÝñïõí üôé õðÜñ÷åé ëüãïò ðïõ Ý÷ù êÜðïôå óôéò ìáýñåò ìïõ, Þ ðïõ êÜðïôå Ý÷ù íåýñá.

Ôï ôñßôï Üôïìï óôï ïðïßï ìßëçóá, Þôáí ï ãéá Ýíá ÷ñüíï åñùôéêüò ìïõ óýíôñïöïò-åß÷á ôçí áíçóõ÷ßá üôé êüëëçóá áðü áõôüí êáé Þèåëá íá åîåôáóôåß êáé ï ßäéïò. Ôï äéêü ôïõ áðïôÝëåóìá Þôáí áñíçôéêü. Ìïõ åßðå üôé èá Þôáí äßðëá ìïõ óå üôé ÷ñåéáæüìïõí. ÁñíÞèçêå üìùò íá Ýñèåé îáíÜ óå óåîïõáëéêÞ åðáöÞ ìáæß ìïõ.
Öïâüôáíå ðïëý, äéêáéïëïãçìÝíá ßóùò. ÌåôÜ áðü ëßãï êáéñü áðïöÜóéóå íá ÷ùñßóïõìå. Ç åñùôéêÞ áðüññéøç ìå áéôßá ôï HIV, åßíáé ßóùò áðü ôá ÷åéñüôåñá óõíáéóèÞìáôá ðïõ ìðïñåß íá âéþóåé ï Üíèñùðïò... ÅéäéêÜ üôáí åßóáé åñùôåõìÝíïò, üôáí íéþèåéò ðùò âñÞêåò ôïí Üíèñùðï ôçò æùÞò óïõ.

ÌåôÜ áðï ìÞíåò, ôïí ðáñáêÜëåóá íá äéáêüøïõìå êÜèå åðáöÞ, áêüìá êáé ôçëåöùíéêÞ. ¢ôïìá Ýñ÷ïíôáé êáé ìïõ ëÝíå üôé áêïýóáíå ðùò ðçãáßíåé ìå äéÜöïñïõò, êáé áõôü ìå ðëçãþíåé ôüóï ðïëý. ÓêÝöôïìáé êáé ëÝù... ðþò îÝñåé üôé áõôïß åßíáé õãéåßò... Êáé åîÜëëïõ, ôïí Ýíá ÷ñüíï ðïõ âãáßíáìå, åß÷á áðü ïôé öáßíåôáé Þäç ôïí éü, êáé äåí Ýðáèå ôßðïôá áõôüò äéüôé ðáßñíáìå ðÜíôá ðñïöõëÜîåéò. Ãéáôß ü÷é êáé ôþñá?

ÊáôÜ äéáóôÞìáôá ìå ðáßñíåé ôçëÝöùíï áëëÜ åãþ äåí áðáíôþ. Äéüôé ôï íá ìçí ôïí Ý÷ù ãéá åñáóôÞ êáé íá ôïí Ý÷åé êÜðïéïò Üëëïò, äåí ôï äÝ÷ïìáé. Ç áðüññéøç ìå ðëçãþíåé. Áõôüò ï Üíèñùðïò Þôáíå ôá ðÜíôá ãéá ìÝíá. Ãéá Ýíá ÷ñüíï ðïõ Þìáóôáí ìáæß, ðïôÝ äåí óêÝöôçêá íá ôïí áðáôÞóù, äéüôé ìå êÜëõðôå áðüëõôá. ¸÷ïõí ðåñÜóåé 9 ìÞíåò, êáé åßíáé ï ôåëåõôáßïò ìå ôïí ïðïßï åß÷á óåîïõáëéêÞ åðáöÞ.

ËÝíå üôé ï ÷ñüíïò åßíáé ãéáôñüò, óå áõôÞ ôçí ðåñßðôùóç üìùò åßíáé äéáöïñåôéêü... óå áðïññßðôïõí ãéáôß óå èåùñïýí Üññùóôï. Ôåëåõôáßá Üñ÷éóá êáé óêÝöôïìáé ëßãï äéáöïñåôéêÜ. ÌÞðùò áí ìå áãáðïýóå ðñáãìáôéêÜ, êáé áí åßíáé ï Üíèñùðïò ôçò æùÞò ìïõ üðùò ëÝù, äåí èá Ýìåíå ìáæß ìïõ Ýôóé êé áëëéþò? ÌÞðùò áõôüò ðïõ èá áîßæåé ôçí áãÜðç ìïõ, èá ðñÝðåé íá ìå äå÷ôåß ìáæß ìå ôï ðñüâëçìá ìïõ?

Ìå åîáßñåóç ôï åñùôéêü èÝìá, óå üëïõò ôïõò Üëëïõò ôïìåßò ôçò æùÞò ìïõ êáôÜöåñá íá óôáèþ óôá ðüäéá ìïõ. ÁñêåôÝò öïñÝò ðéÜíù ôïí åáõôü ìïõ íá Ý÷åé ðåñéóóüôåñç èÝëçóç ãéá æùÞ êáé äçìéïõñãßá áðü üôé ðáëéüôåñá!

ÊáôÜöåñá íá îõðíÜù ôï ðñùß êáé íá ðçãáßíù óôç äïõëåéÜ ìïõ ìå üñåîç. Åßðá óôïí åáõôü ìïõ "ôþñá åßóáé õãéÞò. Ãéá ôþñá, êáé ãéá üóï èá åßóáé õãéÞò, èá æåéò ôç æùÞ óïõ ìå áéóéïäïîßá êáé åíÝñãåéá. Èá âïçèÜò êáé èá äßíåéò áãÜðç óôïõò ãýñù óïõ. Èá ÷áßñåóáé ôçí êÜèå óôéãìÞ ðïõ ðåñíÜ, äçìéïõñãéêÜ".
Êáé óôï êÜôù-êÜôù... áí áõôÞ ç áóèÝíåéá ìå ïäçãåß óôïí èÜíáôï, ìÞðùò åßíáé êáíåßò áèÜíáôïò?
¸ðåéôá, áêïýò ìÝñá ðáñÜ ìÝñá ãéá êáñêßíïõò, ðïõ óå áöÞíïõí óôïí ôüðï ìÝóá óå ëßãïõò ìÞíåò-êáé äåí åßíáé ëßãá ôá ðåñéóôáôéêÜ. Áêïýò ãéá áõôïêéíçôéóôéêÜ... Ýíá óùñü èáíáôçöüñá ãýñù ìáò.

Åãþ Ý÷ù ìéá óïâáñÞ áóèÝíåéá, áëëÜ åëÝã÷åôáé. ÔïõëÜ÷éóôïí Ýôóé ëÝíå ïé ãéáôñïß. Äåí îÝñù áí ìáò ðáñáìõèéÜæïõí êé áõôïß. Åãþ ðÜíôùò èá êÜíù üôé ðåñíÜ áðï ôï ÷Ýñé ìïõ ãéá íá ôçí åëÝãîù. Ôá õðüëïéðá åßíáé áöçìÝíá óôç ìïßñá.

¸íáò ïñïèåôéêüò áíôéìåôùðßæåé áñêåôÜ ðñïâëÞìáôá. Óôï óôÜäéï ðïõ âñßóêïìáé- ôï ðñüâëçìá ðïõ áíôéìåôùðßæù åßíáé ôï øõ÷ïëïãéêü. Åßíáé áñêåôÝò óôéãìÝò áóÞêùôåò, åßíáé üìùò êáé Üëëåò êáëýôåñåò.. ðïõ îå÷íéÝóáé.

Óôçí áñ÷Þ, áõôü ðïõ ìå áíçóõ÷ïýóå Þôáí ôï üôé ôï åß÷á óôï ìõáëü ìïõ óõíÝ÷åéá. Óôçí êÜèå ìïõ êßíçóç, óêåöôüìïõíá áõôü. ÅííÝá ìÞíåò ìåôÜ, åßíáé üðùò ôï öïâüìïõíá áñ÷éêÜ. Äåí óïõ öåýãåé ðïôÝ áðü ôï ìõáëü, åßíáé ðÜíôá åêåß êïëëçìÝíï. ÁðëÜ ðñÝðåé íá ìÜèåéò íá æåéò ìå áõôÞ ôç óêÝøç. Êáé íá âñßóêåéò êÜðïéåò óôéãìÝò ìå ôéò ïðïßåò íá ìðïñåßò íá îåöåýãåéò ëßãï.

ÊáëÞ äýíáìç óå üëïõò êáé ðÜíôá íá åßóôå ÷áñïýìåíïé.




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò